abstract

• A 17-year-old girl with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with persistent minimal residual disease (MRD) who underwent standard chemotherapy was found to have a BCR-ABL1-like gene expression pattern. Genome sequencing revealed a JAK2 mutation not previously described in BCP-ALL and a potential therapeutic target. Due to concern for an on-therapy relapse, the JAK2 inhibitor ruxolitinib was incorporated into a modified chemotherapy backbone to achieve complete remission prior to stem cell transplant. Treatment was well tolerated and she had undetectable MRD prior to a matched allogeneic stem cell transplant and remained in remission at day +100.© 2016 Wiley Periodicals, Inc.

authors

• Mayfield, Jodi
• Czuchlewski, David R
• Gale, James M
• Matlawska-Wasowska, Ksenia
• Vasef, Mohammad A
• Nickl, Christian K
• Pickett, Gavin
• Ness, Scott
• Stuart S. Winter, MD

publication date

• November 2016

Digital Object Identifier (DOI)

• 10.1002/pbc.26328

PubMed ID

• 27860260

start page

end page

volume

number